3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
3
Triple Negative Breast Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Urinary Bladder Neoplasms
1
Turcot syndrome
1
Thyroid Neoplasms
1
Tertiary Lymphoid Structures
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Prostatic Neoplasms
1
Neoplasm Metastasis
1
Mesothelioma, Malignant
1
Lymphoma, T-Cell, Peripheral
1
Inhibition of Autophagy Synergizes Anti-tumor Effect
1
Immunoblastic Lymphadenopathy
1
Gastrointestinal Neoplasms
1
Gastro-enteropancreatic neuroendocrine tumor
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Digestive System Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Biliary Tract Neoplasms
1
Advanced Solid Tumor Cancer
1
Interventions
Capecitabine
6
Irinotecan
5
Fluorouracil
5
Cisplatin
5
Oxaliplatin
4
Leucovorin
4
Gemcitabine
4
apatinib
3
Sorafenib
3
Bevacizumab
3
tislelizumab
2
pembrolizumab
2
Sunitinib
2
Radiotherapy
2
Paclitaxel
2
Immune Checkpoint Inhibitors
2
Cyclophosphamide
2
Cetuximab
2
Aspirin
2
Ascorbic Acid
2
130-nm albumin-bound paclitaxel
2
spartalizumab
1
sintilimab
1
regorafenib
1
pyrotinib
1
pemigatinib
1
lutetium Lu 177 dotatate
1
huachansu
1
halofantrine
1
guadecitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Digestive System Neoplasms
×
Clinical Trials, Phase II as Topic
×
Clear all
NCT06621277
2024-10-15
JUMP_START
University Hospital Heidelberg
Recruiting
250 enrolled